Abstract
Background
Several studies and a meta-analysis showed that fibrin sealant patches reduced lymphatic drainage after various lymphadenectomy procedures. Our goal was to investigate the impact of these patches on drainage after axillary dissection for breast cancer.
Methods
In a phase III superiority trial, we randomized patients undergoing breast-conserving surgery at 14 Swiss sites to receive versus not receive three large TachoSil® patches in the dissected axilla. Axillary drains were inserted in all patients. Patients and investigators assessing outcomes were blinded to group assignment. The primary endpoint was total volume of drainage.
Results
Between March 2015 and December 2016, 142 patients were randomized (72 with TachoSil® and 70 without). Mean total volume of drainage in the control group was 703 ml [95% confidence interval (CI) 512–895 ml]. Application of TachoSil® did not significantly reduce the total volume of axillary drainage [mean difference (MD) −110 ml, 95% CI −316 to 94, p = 0.30]. A total of eight secondary endpoints related to drainage, morbidity, and quality of life were not improved by use of TachoSil®. The mean total cost per patient did not differ significantly between the groups [34,253 Swiss Francs (95% CI 32,625–35,880) with TachoSil® and 33,365 Swiss Francs (95% CI 31,771–34,961) without, p = 0.584]. In the TachoSil® group, length of stay was longer (MD 1 day, 95% CI 0.3–1.7, p = 0.009), and improvement of pain was faster, although the latter difference was not significant [2 days (95% CI 1–4) vs. 5.5 days (95% CI 2–11); p = 0.2].
Conclusions
TachoSil® reduced drainage after axillary dissection for breast cancer neither significantly nor relevantly.
Similar content being viewed by others
References
Droeser RA, Frey DM, Oertli D et al. Volume-controlled vs no/short-term drainage after axillary lymph node dissection in breast cancer surgery: a meta-analysis. Breast. 2009;18:109–14.
He XD, Guo ZH, Tian JH et al. Whether drainage should be used after surgery for breast cancer? A systematic review of randomized controlled trials. Med Oncol. 2011;28(Suppl 1):S22–30.
Gauthier T, Garuchet-Bigot A, Marin B et al. Lanreotide autogel 90 mg and lymphorrhea prevention after axillary node dissection in breast cancer: a phase III double blind, randomized, placebo-controlled trial. Eur J Surg Oncol. 2012;38(10):902–9.
O’Hea BJ, Ho MN, Petrek JA. External compression dressing versus standard dressing after axillary lymphadenectomy. Am J Surg. 1999;177:450–3.
Shamley DR, Barker K, Simonite V, et al. Delayed versus immediate exercises following surgery for breast cancer: a systematic review. Breast Cancer Res Treat. 2005;90:263–71.
van Bemmel AJ, van de Velde CJ, Schmitz RF, et al. Prevention of seroma formation after axillary dissection in breast cancer: a systematic review. Eur J Surg Oncol. 2011;37:829–35.
Cipolla C, Fricano S, Vieni S, et al. Does the use of fibrin glue prevent seroma formation after axillary lymphadenectomy for breast cancer? A prospective randomized trial in 159 patients. J Surg Oncol. 2010;101:600–3.
Gilly FN, Francois Y, Sayag-Beaujard AC, et al. Prevention of lymphorrhea by means of fibrin glue after axillary lymphadenectomy in breast cancer: prospective randomized trial. Eur Surg Res. 1998;30:439–43.
Ko E, Han W, Cho J, et al. Fibrin glue reduces the duration of lymphatic drainage after lumpectomy and level II or III axillary lymph node dissection for breast cancer: a prospective randomized trial. J Korean Med Sci. 2009;24:92–6.
Ruggiero R, Procaccini E, Gili S, et al. Fibrin glue to reduce seroma after axillary lymphadenectomy for breast cancer. Min Chir. 2008;63:249–54.
Swan MC, Oliver DW, Cassell OC, et al. Randomized controlled trial of fibrin sealant to reduce postoperative drainage following elective lymph node dissection. Br J Surg. 2011;98:918–24.
Taflampas P, Sanidas E, Christodoulakis M, et al. Sealants after axillary lymph node dissection for breast cancer: good intentions but bad results. Am J Surg. 2009;198:55–8.
Carless PA, Henry DA. Systematic review and meta-analysis of the use of fibrin sealant to prevent seroma formation after breast cancer surgery. Br J Surg. 2006;93:810–9.
Buda A, Fruscio R, Pirovano C, et al. The use of TachoSil for the prevention of postoperative complications after groin dissection in cases of gynecologic malignancy. Int J Gynaecol Obstet. 2012;117:217–9.
15. Buda A, Ghelardi A, Fruscio R, et al. The contribution of a collagen-fibrin patch (Tachosil) to prevent the postoperative lymphatic complications after groin lymphadenectomy: a double institution observational study. Eur J Obstet Gynecol Reprod Biol. 2016;197:156–8.
Di MG, Caraco C, Crispo A, et al. Collagen sealant patch to reduce lymphatic drainage after lymph node dissection. World J Surg Oncol. 2012;10:275.
Navarro-Rodriguez E, Gomez-Luque I, Diaz-Jimenez N, et al. Effectiveness of an absorbable fibrin sealant patch to reduce lymphoceles formation after axillary lymphadenectomy for breast cancer: a matched-pair analysis. Am J Surg. 2014;208:824–30.
Pinero-Madrona A, Castellanos-Escrig G, Abrisqueta-Carrion J, et al. Prospective randomized controlled study to assess the value of a hemostatic and sealing agent for preventing seroma after axillary lymphadenectomy. J Surg Oncol. 2016;114:423–7.
Gasparri ML, Ruscito I, Bolla D, et al. The efficacy of fibrin sealant patches in reducing the incidence of lymphatic morbidity after radical lymphadenectomy: a meta-analysis. Int J Gynecol Cancer. 2017;27:1283–92.
Mangram AJ, Horan TC, Pearson ML, et al. Guideline for prevention of surgical site infection, 1999. Hospital infection control practices advisory committee. Infect Control Hosp Epidemiol. 1999;20:250–78.
EQ-5D-3L User Guide. Basic information on how to use the EQ-5D-3L instrument. https://euroqol.org/wp-content/uploads/2016/09/EQ-5D-3L_UserGuide_2015.pdf. Accessed 1 Jan 2018.
Cleeland CS, Ryan KM. Pain assessment: global use of the brief pain inventory. Ann Acad Med Singap. 1994;23:129–38.
Antonio M, Pietra T, Domenico L, et al. Does LigaSure reduce fluid drainage in axillary dissection? A randomized prospective clinical trial. Ecancermedicalscience. 2007;1:61.
Chintamani, Singhal V, Singh J, et al. Half versus full vacuum suction drainage after modified radical mastectomy for breast cancer- a prospective randomized clinical trial [ISRCTN24484328]. BMC Cancer. 2005;5:11.
Classe JM, Berchery D, Campion L, et al. Randomized clinical trial comparing axillary padding with closed suction drainage for the axillary wound after lymphadenectomy for breast cancer. Br J Surg. 2006;93:820–4.
Cortadellas T, Cordoba O, Espinosa-Bravo M, et al. Electrothermal bipolar vessel sealing system in axillary dissection: a prospective randomized clinical study. Int J Surg. 2011;9:636–40.
Yang Y, Gao E, Liu X, et al. Effectiveness of OK-432 (Sapylin) to reduce seroma formation after axillary lymphadenectomy for breast cancer. Ann Surg Oncol. 2013;20(5):1500–4.
Zavotsky J, Jones RC, Brennan MB, et al. Evaluation of axillary lymphadenectomy without axillary drainage for patients undergoing breast-conserving therapy. Ann Surg Oncol. 1998;5:227–31.
Barry M, Weber WP, Lee S, et al. Enhancing the clinical pathway for patients undergoing axillary lymph node dissection. Breast. 2012;21:440–3.
Baas-Vrancken Peeters MJ, Kluit AB, Merkus JW, et al. Short versus long-term postoperative drainage of the axilla after axillary lymph node dissection. A prospective randomized study. Breast Cancer Res Treat. 2005;93:271–5.
Dalberg K, Johansson H, Signomklao T, et al. A randomised study of axillary drainage and pectoral fascia preservation after mastectomy for breast cancer. Eur J Surg Oncol. 2004;30:602–9.
Gong Y, Xu J, Shao J, et al. Prevention of seroma formation after mastectomy and axillary dissection by lymph vessel ligation and dead space closure: a randomized trial. Am J Surg. 2010;200:352–6.
Briceno J, Naranjo A, Ciria R, et al. A prospective study of the efficacy of clinical application of a new carrier-bound fibrin sealant after liver resection. Arch Surg. 2010;145:482–8.
Fischer L, Seiler CM, Broelsch CE, et al. Hemostatic efficacy of TachoSil in liver resection compared with argon beam coagulator treatment: an open, randomized, prospective, multicenter, parallel-group trial. Surgery. 2011;149:48–55.
Frilling A, Stavrou GA, Mischinger HJ, et al. Effectiveness of a new carrier-bound fibrin sealant versus argon beamer as haemostatic agent during liver resection: a randomised prospective trial. Langenbecks Arch Surg. 2005;390:114–20.
Genyk Y, Kato T, Pomposelli JJ, et al. Fibrin sealant patch (Tachosil) vs oxidized regenerated cellulose patch (Surgicel original) for the secondary treatment of local bleeding in patients undergoing hepatic resection: a randomized controlled trial. J Am Coll Surg. 2016;222:261–8.
Kakaei F, Seyyed Sadeghi MS, Sanei B, et al. A randomized clinical trial comparing the effect of different haemostatic agents for haemostasis of the liver after hepatic resection. HPB Surg. 2013;2013:587–608.
Rickenbacher A, Breitenstein S, Lesurtel M, et al. Efficacy of TachoSil a fibrin-based haemostat in different fields of surgery—a systematic review. Expert Opin Biol Ther. 2009;9:897-907.
Berger A, Tempfer C, Hartmann B, et al. Sealing of postoperative axillary leakage after axillary lymphadenectomy using a fibrin glue coated collagen patch: a prospective randomised study. Breast Cancer Res Treat. 2001;67:9–14.
Acknowledgment
The authors thank Andreas Gyr for his assistance in writing the manuscript and Daniele Oberti for his assistance in coordinating the study. Funding received for this work from the Swiss Cancer League, the Swiss Secretariat for Education, Research and Innovation (SERI), and Takeda Pharmaceuticals International AG.
Author information
Authors and Affiliations
Consortia
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Weber, W.P., Tausch, C., Hayoz, S. et al. Impact of a Surgical Sealing Patch on Lymphatic Drainage After Axillary Dissection for Breast Cancer: The SAKK 23/13 Multicenter Randomized Phase III Trial. Ann Surg Oncol 25, 2632–2640 (2018). https://doi.org/10.1245/s10434-018-6556-9
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-018-6556-9